Please login to the form below

Envision Pharma Group acquires doDOC to enable seamless document collaboration as part of iEnvision, its global medical affairs platform

doDOC is a leader in document collaborative review, editing, and authoring

London, UK, March 18, 2021

Envision Pharma Group (“Envision” or the “Company”), a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring.

doDOC is an innovative, best-in-class, Software as a Service (SaaS)-based platform that enables simultaneous collaboration in the review, editing, and authoring of documents among multiple users. Designed for the pharma and life sciences industries, it offers significant industry-specific advantages over general document authoring solutions in the market today.

While customers will have the choice to deploy doDOC standalone, the solution will be seamlessly integrated with Envision’s leading medical affairs platform, iEnvision. This unlocks the huge potential for customers to allow real time in-line editing of medical affairs documents, delivering efficiency gains of around 70% versus document processes without doDOC.

Founded in 2015 in Boston, MA, with a European base in Coimbra, Portugal, the company will operate as a business unit under its current brand and will continue to be led by doDOC CEO and co-founder, Federico Cismondi.

David Thompson, CEO, Envision, said, “Bringing doDOC into the Envision family enables us to continue to increase our innovative technology offerings to support life science companies’ goals in becoming ever more efficient and effective in the communication of key scientific data. doDOC is the standout company in its field and, critically, shares our values and commitment to working collaboratively to provide smart solutions that ensure our clients’ success. It will also allow us to consider developing capabilities that enable us to spread beyond our medical affairs client base, including supporting client commercial activities.”

“Envision’s acquisition of doDOC is great for our customers and employees. It allows doDOC to join a proven medical affairs technology leader and advance our solutions for the industry,” said Federico Cismondi, CEO, doDOC. “Most importantly, our companies share a commitment to provide industry-leading innovate solutions and to work together in a collaborative way to ensure our customers’ success.”

Manish Goel, Global Head of Envision Technology Solutions, added, “With our first clients now live on an integrated doDOC and iEnvision platform, we have a capability that no one else in the market can credibly claim as part of their solution. With doDOC as part of Envision Pharma Group, we can broaden our technology capabilities, creating efficiencies for clients and adding value as a strategic partner to deepen our client relationships.”

-- Ends --

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, innovative technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility. Envision Pharma Group provides services and technology solutions to more than 90 companies, including all of the top 20 pharmaceutical companies.

Envision has 20 offices: seven in the United Kingdom – Bishop’s Stortford, Glasgow, Horsham, London (Battersea and Hammersmith), Wilmslow, and Alderley Edge; one in Serbia – Subotica; one in Hungary – Szeged; one in Coimbra, Portugal, eight in the United States – Fairfield and Glastonbury, CT, Philadelphia and Wyomissing, PA, Warren, NJ, Boston and Melrose, MA, Powell, OH; and two in the Asia-Pacific region – Tokyo and Sydney. The company employs over 1000 team members, including over 250 highly qualified and experienced in-house medical writers, and 190 technology solutions team members who provide software development and customer support. To find out more, visit www.envisionpharmagroup.com.

For further information, contact:

Marsha Caplin
Global Head of Marketing
Envision Pharma Group
Email:
marsha.caplin@envisionpharmagroup.com
Tel: +44 (0)7557 083549

About doDOC
Founded by MIT alumni in 2015 in Boston, MA, and with a European base in Coimbra, doDOC has the mission to transform the way life sciences teams write and review their documents, offering cloud-based software for enterprise documentation.

By giving teams the power to control permissions on a granular level, have full traceability on edits and comments, automate tasks, and benefit from flexible integrations that build on top of existing systems, doDOC helps cut more than 70% of the time needed to write and review a document.

The company serves enterprise clients in diverse industries, with its main focus on pharmaceutical and biotechnology companies. It currently works with top pharmaceutical companies worldwide, with the best examples in medical, scientific, regulatory, and legal writing. To find out more, visit www.dodoc.com.

For further information, contact: Raquel Pinto
Head of Marketing
doDOC
Email:
marketing@dodoc.com
Tel: +351 937379227

18th March 2021

Share

Tags

Company Details

Envision Pharma Group

01403 322 000

Contact Website

Address:
Envision House
5 North Street
Horsham
West Sussex
RH12 1XQ
England

Latest content on this profile

Envision Pharma Group acquires doDOC to enable seamless document collaboration as part of iEnvision, its global medical affairs platform
doDOC is a leader in document collaborative review, editing, and authoring
Envision Pharma Group
Envision Pharma Group appoints Manish Goel as Global Head of Envision Technology Solutions
Goel will drive the development of innovative technologies, and joins Envision from IQVIA where he served as the VP of Technology Solutions
Envision Pharma Group
Envision Pharma Group acquires Two Labs to advance its position as a global strategic partner to pharma and create a unique and unrivaled launch excellence offering
Acquisition follows increased investment in Envision from GHO Capital and its partners
Envision Pharma Group
GHO Capital and management acquire Ardian majority stake in Envision Pharma Group to accelerate continued growth
Move set to advance Envision’s global ambition to be the leading strategic partner in medical affairs
Envision Pharma Group
Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
The PM Society Digital Awards 2020 saw Envision pick up two Silver awards for Congress, Meetings & Events and for Innovation – Creativity as a result of its “See through diabetes” work in collaboration with Mundipharma.
Envision Pharma Group
90TEN acquired by Envision Pharma Group
90TEN’s award-winning behavioral science-led communications group will help deliver a deeper and more diversified offering to Envision’s clients, while bringing significant geographical expansion opportunities for the London-based team.
Envision Pharma Group